Geoffrey Erickson, PhD

Prior to OncoCellMDx, Geff was a Director of Business Development at Harvard University. Prior to joining Harvard, Geff led other companies including CEO of Cytex Therapeutics, Inc., a company spun out of Duke University, and President and CEO of Humacyte, Inc., a company created from technology licensed out of Duke University and MIT. Prior to these roles, he was a venture capitalist with Pappas Ventures, a firm focused on investments in the life science industry. Through Pappas Ventures, he was a founder of Colucid Pharmaceuticals that was acquired by Eli Lilly in 2017. Geff received a BSE in engineering from Duke University, an MSE in biomedical engineering from Tulane University, and a PhD in biomedical engineering from Duke University.